Skip to main content
Air Liquide
Air Liquide worldwide
Please select

Electronics

View

Engineering & Construction

View

Large projects

View

Cardio Pulmonary Ventilation

An innovative ventilation solution against cardiac arrest

Every year, 50,000 people die prematurely from a cardiac arrest in France. The survival rate without after-effects to a cardiac arrest does not exceed 5%. In view of this situation, Air Liquide has developed a new offer that facilitates the care of the victims. Explanation.

In partnership with the Annecy Genevois Hospital in France, Air Liquide has developed the first ventilator dedicated to cardiopulmonary resuscitation, specifically designed to act as an intelligent assistant to first-aid workers, accident and emergency doctors and clinicians when treating victims of cardiac arrest. The CPV (Cardio Pulmonary Ventilation) system was designed following the immersion of Air Liquide people in the emergency services to meet the specific needs of these teams.

A system designed following the immersion of Air Liquide people in emergency services

An improved care

To optimize ventilation, which is essential during cardiopulmonary resuscitation, the CPV innovation combines, for the first time in one ventilator, continuous thoracic compression, effective ventilation and dedicated monitoring1. Therefore, the entire system contributes to improving the quality of patient care. Unlike the manual insufflator, CPV is an entirely automated method that frees up the practitioner’s hands. The latter can then concentrate on coordinating the team, managing the patient and his/her family.

A real-time support

The clinical indicators of the person being treated, visible in real time on the ventilator screen, are used to guide the teams: CPV shows whether faster or softer compression is needed and encourages the cardiac massage to be interrupted as little as possible. Oxygenation and ventilation are improved and the effectiveness of the cardiac massage is optimized. In France, more than one hundred cardiac arrest patients have already benefited from treatment including this specific and innovative ventilation method. Air Liquide is also targeting export markets and is continuing its approach of co-innovation with international research centers, in Canada in particular.

1 Display of information such as the quality of compressions and the fraction of CO2 expired.

In France, over 100 cardiac arrest patients have already benefited from this innovative ventilation method